The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Secondary analysis of PURE-01: Role of FDG-PET/CT in evaluating lymph node involvement of patients with muscle invasive bladder cancer (MIBC) receiving neoadjuvant pembrolizumab and radical cystectomy (RC).
 
Laura Marandino
No Relationships to Disclose
 
Antonella Capozza
No Relationships to Disclose
 
Alberto Briganti
Consulting or Advisory Role - Astellas Pharma; Ferring; Janssen-Cilag; MDxHealth; OPKO Health
Research Funding - Sandoz-Novartis
 
Daniele Raggi
No Relationships to Disclose
 
Elena Farè
No Relationships to Disclose
 
Filippo Pederzoli
No Relationships to Disclose
 
Andrea Gallina
No Relationships to Disclose
 
Marco Bandini
No Relationships to Disclose
 
Umberto Capitanio
No Relationships to Disclose
 
Marco Bianchi
No Relationships to Disclose
 
Giorgio Gandaglia
No Relationships to Disclose
 
Nicola Fossati
No Relationships to Disclose
 
Patrizia Giannatempo
No Relationships to Disclose
 
Ettore Seregni
No Relationships to Disclose
 
Andrea Salonia
Speakers' Bureau - Astellas Pharma
Travel, Accommodations, Expenses - Konpharma
 
Francesco Montorsi
No Relationships to Disclose
 
Alessandra Alessi
No Relationships to Disclose
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)